Levetiracetam
Product Images NDC 68788-7592

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-7592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
The figure shows the Responder Rate in Study 1 with a 250% reduction from baseline. The percentages range from 0% to 39.6%, with a statistically significant difference from the placebo. The text also mentions the names Leviaseam and Levieacl with corresponding quantities in ooy.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
The text describes Figure 2 showing the Responder Rate (250% Reduction from Baseline) in Study 2, Period A. It presents a graph with the percentages of patients who responded to the treatment with Levetiracetam 1000 mg/day and Levetiracetam 2000 mg/day, as well as the placebo, indicating that the differences in response rates between Levetiracetam and placebo were statistically significant.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a chart displaying the responder rate, which indicates a reduction of over 50% from baseline, in Study 3. The chart compares the responder rates for the group that received a placebo (N=104) and the group that received Levetiracetam 3000 mg/day (N=180). The responder rate for the Levetiracetam group was 45%, which was statistically significant compared to the placebo group's responder rate of 14.4%. However, there was no responder rate indicated for the group who received the placebo or Levetiracetam.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
This is a graph showing the Responder Rate in Study 4 for a Placebo group and a group taking Levetiracetam. The Responder Rate is defined as a 50% reduction from the baseline. The percentages are shown on the y-axis and range from 0% to 50%. The Placebo group had a Responder Rate of 19.6%, while the Levetiracetam group had a Responder Rate of 44.6%. The Levetiracetam group had statistically significant results compared to the placebo group.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This figure shows the responder rate for patients aged 1 month to less than 4 years in Study 5, with a reduction of over 50% from baseline. The percentages are obscured by illegible characters. The study compared Lovetracatam to placebo, and Lovetracatam was found to be statistically significant.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a figure labeled as "Figure 6" which shows the responder rate of patients with PGTC seizure frequency per week in Study 7. The figure displays a graph with a range of percentages from 0% to 100%. Two bars are compared, one labeled "Placebo" with 84 patients and the other labeled "Levetiracetam" with 79 patients. The graph shows that the Levetiracetam group had a 72.2% reduction from baseline in PGTC seizure frequency per week, which is statistically significant compared to the placebo. The percentage of patients who responded to Levetiracetam treatment is 45.2%. Approximately 9% of patients did not respond to either treatment.*
FDA Label Image

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.